A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
Paolo Giovanni Nuciforo, Tomás Pascual, Javier Cortés et al. · Annals of Oncology · 2017
Cited by 111 works. doi:10.1093/annonc/mdx647
Authors
- Paolo Giovanni Nuciforo
- Tomás Pascual
- Javier Cortés
- Antonio Llombart‐Cussac
- Roberta Fasani
- Laia Paré
- Mafalda Oliveira
- Patricia Galván
- Noelia Martínez-Jáñez
- Begoña Bermejo
- María Vidal
- Sònia Pernas
- Rafael López‐López
- Montserrat Muñoz-Mateu
- Isabel Garau
- Luís Manso
- Jesús Alarcón
- Vanessa S. Rodrik-Outmezguine
- Jan C. Brase
References
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
- Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance